secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093237
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology Q2 net loss $18.9M; cash $552.9M; positive CORE-001 combo data published in Nature Medicine
--------------------------------------------------------------------------------

- Net loss of $18.9M ($0.28 EPS) vs $11.6M loss ($3.93 EPS) in Q2 2023; R&D spend $18.5M vs $9.8M YoY.
- Cash, equivalents and marketable securities $552.9M as of June 30, 2024; runway expected through 2027.
- CORE-001 (cretostimogene + pembrolizumab) achieved 54% complete response at 24 months; 100% progression-free survival at 24 months.
- BOND-003 monotherapy showed 75.2% CR at any time (n=105); no Grade 3+ AEs or treatment-related discontinuations.
- Expanded Access Program initiated first patient dosed in June; primary BOND-003 results expected by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000095017024093237/0000950170-24-093237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000095017024093237/ck0001991792-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer